As transfer of M002-treated CD4+ T cells compared to transfer of a same number of saline-treated control cells preferentially reduced tumor cells, but not other immune cells, the MHCII-dependent anti-tumor activity may suggest an expansion of tumor-specific CD4+ T cells by M002 treatment, supporting the intrinsic epitope spreading induced by OV therapy51,52. The gene discussed is CD4; the disease is neoplasm.